Add to ORKGPooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV
Abstract: Palonosetron, the second generation 5-hydroxytryptamine-3 receptor antagonist (5-HT3RA), h...
Figure S1. The structure of the category and effect measurement of CINV. The CR rates in the TRIPLE ...
PURPOSE: The control of nausea and vomiting induced by chemotherapy is paramount for overall treatme...
Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the pr...
Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemoth...
Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women recei...
BACKGROUND: APF530 is a novel sustained-release formulation of granisetron. In a Phase III trial, AP...
BACKGROUND: APF530 is a novel sustained-release formulation of granisetron. In a Phase III trial, AP...
Palonosetron versus ondansetron as rescue medication for postoperative nausea and period favoring pa...
BACKGROUND: APF530 is a novel sustained-release formulation of granisetron. In a Phase III trial, AP...
BACKGROUND: APF530 is a novel sustained-release formulation of granisetron. In a Phase III trial, AP...
Purpose: Chemotherapy-induced nausea and vomiting (CINV) is a side effect related to administration ...
PURPOSE: Chemotherapy-induced nausea and vomiting (CINV) is a side effect related to administration ...
Purpose: Chemotherapy-induced nausea and vomiting (CINV) is a side effect related to administration ...
Purpose: Chemotherapy-induced nausea and vomiting (CINV) is a side effect related to administration ...
Abstract: Palonosetron, the second generation 5-hydroxytryptamine-3 receptor antagonist (5-HT3RA), h...
Figure S1. The structure of the category and effect measurement of CINV. The CR rates in the TRIPLE ...
PURPOSE: The control of nausea and vomiting induced by chemotherapy is paramount for overall treatme...
Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the pr...
Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemoth...
Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women recei...
BACKGROUND: APF530 is a novel sustained-release formulation of granisetron. In a Phase III trial, AP...
BACKGROUND: APF530 is a novel sustained-release formulation of granisetron. In a Phase III trial, AP...
Palonosetron versus ondansetron as rescue medication for postoperative nausea and period favoring pa...
BACKGROUND: APF530 is a novel sustained-release formulation of granisetron. In a Phase III trial, AP...
BACKGROUND: APF530 is a novel sustained-release formulation of granisetron. In a Phase III trial, AP...
Purpose: Chemotherapy-induced nausea and vomiting (CINV) is a side effect related to administration ...
PURPOSE: Chemotherapy-induced nausea and vomiting (CINV) is a side effect related to administration ...
Purpose: Chemotherapy-induced nausea and vomiting (CINV) is a side effect related to administration ...
Purpose: Chemotherapy-induced nausea and vomiting (CINV) is a side effect related to administration ...
Abstract: Palonosetron, the second generation 5-hydroxytryptamine-3 receptor antagonist (5-HT3RA), h...
Figure S1. The structure of the category and effect measurement of CINV. The CR rates in the TRIPLE ...
PURPOSE: The control of nausea and vomiting induced by chemotherapy is paramount for overall treatme...